This is a routine board refresh with no financial or operational implications. No trading action warranted. Monitor for any future strategic shifts that Boulud's diagnostics background might influence, but no near-term catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $207.24entry
- T+1 · 6mo ago −2.93%α −3.17% · $201.16
- T+5 · 6mo ago +4.22%α +2.75% · $215.98
- T+20 · 5mo ago +2.47%α +2.44% · $212.35
- T+60 · 3mo ago +12.26%α +9.54% · $232.64
Price Chart
How similar events traded
Executive Summary
STERIS filed an 8-K reporting the retirement of director Richard C. Breeden (not standing for reelection after 18 years) and the appointment of Pierre Boulud, CEO of bioMérieux, to the board. This is a routine board refresh with no material financial impact, no financial data, guidance, or operational changes were disclosed.
Key Facts
- Director Richard C. Breeden will not stand for reelection at the 2026 Annual General Meeting; his retirement is not due to any disagreement with the company.
- Board size increased from 9 to 10 members; Pierre Boulud appointed effective May 5, 2026.
- Pierre Boulud is CEO of bioMérieux (in vitro diagnostics) and previously held senior roles at Ipsen and Boston Consulting Group.
- Boulud will receive a prorated fee of $76,989 in career restricted stock units for the remainder of the board's 2025-26 term.
Financial Impact
No material financial impact. Director compensation of $76,989 in restricted stock units is immaterial for a $21B market cap company.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-212159 |
| Document: d27562dex991.htm | 0001193125-26-212159 |
| Document: 0001193125-26-212159-index-headers.html | 0001193125-26-212159 |
| Document: 0001193125-26-212159-index.html | 0001193125-26-212159 |
| Document: 0001193125-26-212159.txt | 0001193125-26-212159 |
Track record
21 reports on STE
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +17.96% at T+20 after the Oct 13, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $264.32 Now $264.32 +0.00% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $264.32 Now $264.32 +0.00% settles Nov 20
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $264.32 Now $264.32 +0.00% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $253.44 Now $264.32 +4.29% settles Nov 19
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $256.27 Now $264.32 +3.14% settles Nov 18
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $254.12 to $253.44 Now $264.32 +4.01% ▼ −0.27% −3.56% vs SPY
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $254.12 to $253.44 Now $264.32 +4.01% ▼ −0.27% −3.56% vs SPY
- Oct 28, 202619d ago Press Release Neutral 2/10 Entry $232.14 to $254.12 Now $264.32 +13.86% ▲ +9.47% +14.19% vs SPY
- Oct 20, 202627d ago Press Release Neutral 1/10 Entry $221.48 to $228.49 Now $264.32 +19.34% ▲ +3.17% +3.61% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers